2022年V3版《NCCN食管和食管胃结合部癌临床实践指南》更新解读

Interpretation of the NCCN esophageal and esophagogastric junction cancers clinical practice guidelines in oncology(version 3.2022)

目前美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)已更新发布2022年V3版《NCCN食管和食管胃结合部癌临床实践指南》(以下简称为《指南》)的最新内容。该《指南》以高质量的临床证据和最新的研究进展为基础,制定食管和食管胃结合部癌诊治标准,受到了全球临床医师的广泛认可和肯定。相比于2021年V4版《指南》,2022年的3个版本都有了一些更新、修订,主要集中于分子标志物检测、围术期治疗、晚期免疫治疗、放疗等方面。本文将对新版《指南》主要更新内容进行解读。

The National Comprehensive Cancer Network(NCCN)has updated and released the NCCN esophageal and esophagogastric junction cancers clinical practice guidelines in oncology(version 3.2022).Compared with the version 4 of the guidelines in 2021,the 3 versions in 2022 have some updates and revisions,mainly focusing on molecular marker detection,perioperative treatment,advanced immunotherapy,radiotherapy and other aspects.This article will interpret the main content of the new edition of the guidelines,in order to enhance the understanding of the guidelines and guide the clinical practice of diagnosis and treatment.